89Zr-Panitumumab for the Treatment of Patients with Metastatic Pancreatic Cancer

This phase I trial studies the side effects of 89Zr-panitumumab in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). 89Zr panitumumab is an investigational imaging agent that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. 89Zr panitumumab may help surgeons to identify (metastatic) pancreatic cancer prior the surgical procedure with equal or better accuracy than current imaging technologies to be able to better determine which patients should get surgery and which patients may not benefit from surgery (yet).

Inclusion Criteria

Confirmed diagnosis of pancreatic cancer
Age >= 19 years

Exclusion Criteria

Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
History of infusion reactions to monoclonal antibody therapies
Pregnant or breastfeeding
Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Severe renal disease or anuria
Known hypersensitivity to deferoxamine or any of its components

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04833959.

PRIMARY OBJECTIVE:

I. Assess the safety of zirconium Zr 89 panitumumab (89Zr-panitumumab) as a molecular imaging agent in patients with metastatic pancreas cancer.

OUTLINE:

Patients receive 89Zr-panitumumab intravenously (IV) over 1.5-2 hours. After 4-7 days, patients undergo PET/computed tomography (CT) scan over 1-1.5 hours.

After completion of study treatment, patients are followed up at 30 days.

Trial PhasePhase I

Trial Typediagnostic

Lead OrganizationStanford Cancer Institute Palo Alto

Principal InvestigatorAndrei Iagaru

Primary IDPANC0037
Secondary IDsNCI-2021-03447
ClinicalTrials.gov IDNCT04833959

89Zr-Panitumumab for the Treatment of Patients with Metastatic Pancreatic Cancer

Inclusion Criteria

Exclusion Criteria

Have a question?
We're here to help

Which trials are right for you?

89Zr-Panitumumab for the Treatment of Patients with Metastatic Pancreatic Cancer

Description

Eligibility Criteria

Locations & Contacts

Trial Objectives and Outline

Trial Phase & Type

Lead Organization

Trial IDs

Have a question?We're here to help

Which trials are right for you?

Have a question?
We're here to help